MOLN

Molecular Partners AG

Price Chart

Latest Quote

$4.10

+0.19 (+4.86%)

Current Price

Previous Close	$3.91
Open	$4.09
Day High	$4.10
Day Low	$4.09
Volume	762

Fetched: 2026-07-17T02:40:57

Stock Information

Note: Financial values converted from CHF to USD

Shares Outstanding	37.51M
Total Debt	$4.14M
Cash Equivalents	$97.61M
Net Income	$-71.91M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$146.29M
EPS (TTM)	$-1.92
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$70.87M
Income	$-71.91M
Book/sh	$2.26
Cash/sh	$2.10
Employees	134

Financial Ratios

Quick Ratio	9.21
Current Ratio	9.43
Debt/Eq	4.88

Returns & Margins

ROA	-28.82%
ROE	-59.01%

Ownership

Institutional Ownership	9.58%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-14.99
P/B	1.73

Analyst Data

Recommendation	strong_buy
Target Price	$11.06

Technical Indicators

SMA20	$3.95
SMA50	$3.96
SMA200	$4.19
RSI	54.81
ATR	0.1330

Shares Float	19.92M
Short Float	0.01%
Short Ratio	0.24
Volatility	0.67
Rel Volume	0.25

Performance History

Week	-3.08%
Month	-0.51%
Quarter	-6.70%
6 Months	-7.36%
YTD	-7.58%
Year	+6.85%
3 Years	-39.06%
5 Years	-79.55%
10 Years	-80.15%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$3.90	2,200
2026-07-16	$4.10	800
2026-07-15	$3.91	1,600
2026-07-14	$4.00	900
2026-07-13	$4.01	1,400
2026-07-10	$4.02	0
2026-07-09	$4.02	2,300
2026-07-08	$4.09	600
2026-07-07	$4.09	9,100
2026-07-06	$4.00	30,200
2026-07-02	$3.98	46,700
2026-07-01	$3.93	5,300
2026-06-30	$3.87	900
2026-06-29	$3.96	9,100
2026-06-26	$3.80	11,300
2026-06-25	$3.93	3,900
2026-06-24	$3.80	13,900
2026-06-23	$3.81	27,300
2026-06-22	$3.95	7,600
2026-06-18	$3.82	1,000

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

📰 Latest News

Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...

GuruFocus.com • 2026-05-14T01:03:33Z

3 European Penny Stocks With Market Caps Under €600M

Simply Wall St. • 2026-04-06T11:05:11Z

Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready

MarketBeat • 2026-02-02T20:30:57Z

Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company

Simply Wall St. • 2025-09-30T05:47:10Z

Stocks Look Set to Open Trading Session Marginally Lower Wednesday as Investors Look Ahead to Nvidia Earnings

MT Newswires • 2025-08-27T13:26:44Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$6,143,690	$8,700,059	$234,320,597
Operating Revenue	$0	$6,143,690	$8,700,059	$234,320,597
Expenses
Interest Expense	$22,251	$30,904	$42,029	$747,874
Total Expenses	$68,527,489	$81,817,391	$84,239,019	$90,168,854
Other Income Expense	$-9,520,866	$4,734,474	$-6,311,807	$886,323
Net Non Operating Interest Income Expense	$1,840,635	$4,136,175	$5,228,936	$646,509
Total Other Finance Cost	$18,542	$16,070	$18,542	$17,306
Interest Expense Non Operating	$22,251	$30,904	$42,029	$747,874
Operating Expense	$68,527,489	$81,817,391	$84,239,019	$90,168,854
General And Administrative Expense	$18,382,861	$21,217,364	$23,480,764	$26,975,374
Other Operating Expenses	-	-	-	$-54,391
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Net Interest Income	$1,840,635	$4,136,175	$5,228,936	$646,509
Interest Income	$1,881,428	$4,183,149	$5,289,507	$1,411,689
Normalized Income	$-67,498,600	$-71,137,568	$-71,528,203	$144,970,199
Net Income From Continuing And Discontinued Operation	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Total Operating Income As Reported	$-71,850,273	$-75,673,701	$-75,538,960	$144,151,743
Net Income Common Stockholders	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Net Income	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Net Income Including Noncontrolling Interests	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Net Income Continuous Operations	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Pretax Income	$-76,207,720	$-66,803,052	$-76,621,832	$145,684,575
Special Income Charges	$-3,324,021	$0	$0	-
Interest Income Non Operating	$1,881,428	$4,183,149	$5,289,507	$1,411,689
Operating Income	$-68,527,489	$-75,673,701	$-75,538,960	$144,151,743
Depreciation Amortization Depletion Income Statement	$458,614	$517,949	$453,669	$514,240
Depreciation And Amortization In Income Statement	$458,614	$517,949	$453,669	$514,240
Per Share
Diluted EPS	$-2.04	$-1.97	$-2.34	$4.38
Basic EPS	$-2.04	$-1.97	$-2.34	$4.49
Other
Tax Effect Of Unusual Items	$-809,274	$402,430	$-1,218,179	$171,947
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-64,014,287	$-68,578,171	$-67,276,500	$148,498,064
Total Unusual Items	$-9,520,866	$4,734,474	$-6,311,807	$886,323
Total Unusual Items Excluding Goodwill	$-9,520,866	$4,734,474	$-6,311,807	$886,323
Reconciled Depreciation	$2,650,316	$2,928,451	$2,991,495	$2,951,938
EBITDA (Bullshit earnings)	$-73,535,152	$-63,843,697	$-73,588,307	$149,384,387
EBIT	$-76,185,469	$-66,772,148	$-76,579,802	$146,432,449
Diluted Average Shares	$46,073,080	$42,069,499	$40,509,621	$41,121,397
Basic Average Shares	$46,073,080	$42,069,499	$40,509,621	$40,137,900
Diluted NI Availto Com Stockholders	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Tax Provision	$2,472	$2,472	$0	$0
Restructuring And Mergern Acquisition	$3,324,021	$0	$0	-
Gain On Sale Of Security	$-6,196,845	$4,734,474	$-6,311,807	$886,323
Research And Development	$49,686,014	$60,082,078	$60,304,586	$62,733,630
Selling General And Administration	$18,382,861	$21,217,364	$23,480,764	$26,975,374
Other Gand A	$6,284,612	$7,667,869	$9,091,920	$12,403,579
Salaries And Wages	$12,098,249	$13,549,495	$14,388,844	$14,571,795

Fetched: 2026-07-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$99,302,803	$175,024,714	$217,831,526	$290,366,629
Total Assets	$126,220,079	$195,965,180	$245,193,817	$324,191,538
Total Non Current Assets	$6,466,327	$5,249,950	$7,284,661	$9,278,579
Goodwill And Other Intangible Assets	$2,472	$60,572	$262,065	$334,998
Other Intangible Assets	$2,472	$60,572	$262,065	$334,998
Current Assets	$119,753,752	$190,715,230	$237,909,155	$314,912,959
Other Current Assets	$-1,236	-	-	-
Prepaid Assets	$2,366,001	$2,780,113	$3,073,081	$4,833,366
Receivables	$2,354,875	$3,205,350	$3,812,302	$2,098,991
Other Receivables	$187,896	$436,363	$1,479,678	$932,061
Taxes Receivable	$1,854,232	$2,415,447	$1,967,959	$522,894
Accounts Receivable	$312,747	$353,540	$364,666	$644,037
Cash Cash Equivalents And Short Term Investments	$115,034,112	$184,729,767	$231,023,772	$307,980,601
Cash And Cash Equivalents	$102,171,919	$78,958,164	$83,204,357	$108,714,888
Cash Financial	$102,171,919	$78,958,164	$83,204,357	$108,714,888
Other Non Current Assets	-	-	-	-
Debt
Total Debt	$4,504,549	$3,021,163	$4,514,438	$5,995,352
Long Term Debt And Capital Lease Obligation	$3,013,746	$1,516,762	$3,021,163	$4,514,438
Current Debt And Capital Lease Obligation	$1,490,803	$1,504,401	$1,493,275	$1,480,914
Liabilities
Total Liabilities Net Minority Interest	$26,914,803	$20,879,894	$27,100,226	$33,489,911
Total Non Current Liabilities Net Minority Interest	$13,283,722	$7,547,962	$9,279,816	$12,165,001
Other Non Current Liabilities	$1,236	-	-	-
Tradeand Other Payables Non Current	$197,785	$0	-	-
Current Liabilities	$13,631,081	$13,331,932	$17,820,410	$21,324,910
Other Current Liabilities	$1,236	-	-	-
Payables And Accrued Expenses	$12,139,042	$11,827,531	$10,970,876	$11,921,479
Payables	$2,183,050	$2,298,012	$1,641,614	$2,649,080
Other Payable	$1,024,772	$1,458,663	$1,134,790	$1,416,634
Accounts Payable	$1,158,277	$839,349	$506,824	$1,232,447
Current Deferred Liabilities	-	$0	$5,356,260	$7,922,517
Non Current Deferred Liabilities	-	-	$0	$4,495,896
Total Tax Payable	-	-	-	$0
Equity
Common Stock Equity	$99,305,276	$175,085,286	$218,093,590	$290,701,627
Total Equity Gross Minority Interest	$99,305,276	$175,085,286	$218,093,590	$290,701,627
Stockholders Equity	$99,305,276	$175,085,286	$218,093,590	$290,701,627
Retained Earnings	$-385,375,030	$-304,456,323	$-237,038,902	$-157,955,886
Gains Losses Not Affecting Retained Earnings	-	-	-	$-1,212,668
Other Equity Adjustments	-	-	-	$-1,212,668
Other
Treasury Shares Number	$3,662,694	$4,326,542	$4,326,542	-
Ordinary Shares Number	$46,246,620	$45,568,499	$40,613,004	$44,556,844
Share Issued	$49,909,314	$49,895,042	$44,939,546	$44,556,844
Tangible Book Value	$99,302,803	$175,024,714	$217,831,526	$290,366,629
Invested Capital	$99,305,276	$175,085,286	$218,093,590	$290,701,627
Working Capital	$106,122,671	$177,383,298	$220,088,745	$293,588,049
Capital Lease Obligations	$4,504,549	$3,021,163	$4,514,438	$5,995,352
Total Capitalization	$99,305,276	$175,085,286	$218,093,590	$290,701,627
Treasury Stock	$1,395,619	$1,212,668	$1,212,668	$1,212,668
Additional Paid In Capital	$481,085,567	$475,765,156	$451,851,737	$445,415,078
Capital Stock	$4,990,358	$4,989,122	$4,493,423	$4,455,103
Common Stock	$4,990,358	$4,989,122	$4,493,423	$4,455,103
Employee Benefits	$10,070,955	$6,031,200	$6,258,653	$3,154,668
Long Term Capital Lease Obligation	$3,013,746	$1,516,762	$3,021,163	$4,514,438
Current Capital Lease Obligation	$1,490,803	$1,504,401	$1,493,275	$1,480,914
Current Accrued Expenses	$9,955,992	$9,529,519	$9,329,262	$9,272,399
Net PPE	$6,463,854	$5,189,379	$7,022,597	$8,943,581
Accumulated Depreciation	$-24,567,344	$-22,578,371	$-20,201,245	$-18,167,770
Gross PPE	$31,031,199	$27,767,750	$27,223,842	$27,111,351
Leases	$782,486	$782,486	$782,486	$771,361
Other Properties	$27,976,660	$24,250,889	$23,927,016	$11,923,951
Machinery Furniture Equipment	$2,272,053	$2,734,375	$2,514,339	$14,416,040
Properties	$0	$0	$0	$0
Other Short Term Investments	$12,862,193	$105,771,603	$147,819,415	$199,265,714
Current Deferred Revenue	-	$0	$5,356,260	$7,922,517
Non Current Deferred Revenue	-	-	$0	$4,495,896

Fetched: 2026-07-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-64,244,212	$-74,133,452	$-73,938,139	$144,814,322
Operating Activities
Operating Cash Flow	$-63,361,597	$-73,239,711	$-72,939,326	$146,565,954
Cash Flow From Continuing Operating Activities	$-63,359,125	$-73,239,711	$-72,939,326	$146,565,954
Operating Gains Losses	$-674,941	$-828,224	$661,343	$1,417,870
Investing Activities
Capital Expenditure	$-882,615	$-893,740	$-998,813	$-1,751,632
Investing Cash Flow	$89,681,809	$50,046,971	$55,178,251	$-125,001,230
Cash Flow From Continuing Investing Activities	$89,681,809	$50,046,971	$55,178,251	$-125,001,230
Financing Activities
Issuance Of Capital Stock	$0	$21,437,400	$0	$0
Financing Cash Flow	$-1,420,342	$17,841,425	$-1,442,593	$-1,940,763
Cash Flow From Continuing Financing Activities	$-1,420,342	$17,841,425	$-1,442,593	$-1,940,763
Net Common Stock Issuance	$0	$21,437,400	$0	$-780,014
Common Stock Issuance	$0	$21,437,400	$0	$0
Repurchase Of Capital Stock	-	$0	$0	$-780,014
Net Other Financing Charges	-	$-2,152,146	-	-
Other
Repayment Of Debt	$-1,498,220	$-1,493,275	$-1,480,914	$-1,469,788
End Cash Position	$102,171,919	$78,958,164	$83,204,357	$108,714,888
Beginning Cash Position	$78,958,164	$83,204,357	$108,714,888	$88,771,999
Effect Of Exchange Rate Changes	$-1,686,115	$1,105,123	$-6,306,863	$318,928
Changes In Cash	$24,899,870	$-5,351,315	$-19,203,668	$19,623,961
Proceeds From Stock Option Exercised	$77,878	$49,446	$38,321	$309,039
Net Issuance Payments Of Debt	$-1,498,220	$-1,493,275	$-1,480,914	$-1,469,788
Net Long Term Debt Issuance	$-1,498,220	$-1,493,275	$-1,480,914	$-1,469,788
Long Term Debt Payments	$-1,498,220	$-1,493,275	$-1,480,914	$-1,469,788
Interest Received Cfi	$2,134,840	$5,240,061	$4,730,765	$610,661
Net Investment Purchase And Sale	$88,429,584	$45,700,650	$51,446,299	$-123,860,259
Sale Of Investment	$170,359,465	$342,433,477	$394,881,062	$246,265,563
Purchase Of Investment	$-81,929,881	$-296,732,827	$-343,434,763	$-370,125,822
Net Intangibles Purchase And Sale	$0	$-22,251	$-288,024	$-296,677
Purchase Of Intangibles	$0	$-22,251	$-288,024	$-296,677
Net PPE Purchase And Sale	$-882,615	$-871,489	$-710,789	$-1,454,954
Purchase Of PPE	$-882,615	$-871,489	$-710,789	$-1,454,954
Interest Paid Cfo	$-22,251	$-32,140	$-42,029	$-798,556
Change In Working Capital	$1,495,748	$-4,693,681	$-7,429,292	$-7,429,292
Change In Other Working Capital	$-22,251	$-5,404,470	$-7,088,113	$-31,259,888
Change In Other Current Assets	$414,112	$292,969	$1,760,285	$2,209,009
Change In Payables And Accrued Expense	$504,351	$846,766	$-948,131	$-9,608,633
Change In Accrued Expense	$424,001	$199,021	$55,627	$-3,008,801
Change In Payable	$80,350	$647,745	$-1,003,758	$-6,599,832
Change In Receivables	$599,535	$-428,946	$-1,153,333	$31,230,220
Other Non Cash Items	$3,934,681	$-8,885,482	$1,064,329	$-1,550,138
Stock Based Compensation	$5,462,569	$5,074,416	$6,436,659	$6,289,557
Deferred Tax	$2,472	$2,472	$0	$0
Deferred Income Tax	$2,472	$2,472	$0	$0
Depreciation Amortization Depletion	$2,650,316	$2,928,451	$2,991,495	$2,951,938
Depreciation And Amortization	$2,650,316	$2,928,451	$2,991,495	$2,951,938
Amortization Cash Flow	$56,863	$223,744	$360,957	-
Amortization Of Intangibles	$56,863	$223,744	$360,957	-
Depreciation	$2,592,217	$2,704,707	$2,630,538	-
Pension And Employee Benefit Expense	$-674,941	$-828,224	$661,343	$1,417,870
Net Income From Continuing Operations	$-76,210,192	$-66,805,525	$-76,621,832	$145,684,575
Common Stock Payments	-	$0	$0	$-780,014
Taxes Refund Paid	-	$0	$0	$0
Change In Account Payable	-	$647,745	$-1,003,758	$-6,599,832
Change In Prepaid Assets	-	-	-	-

Fetched: 2026-07-17